While current evidence suggests that metformin fails to offer beneficial vascular effects in the long term, its relatively favourable safety profile makes it a valuable adjunctive therapy for T1D patients who are insulin resistant, to enhance insulin sensitivity, reduce weight and insulin requirements, at least in the short term. The gene discussed is INS; the disease is type 1 diabetes mellitus.